We are live on ! Find out more
VFA

Virtus Fund Advisers Portfolio holdings

AUM $32.1M
1-Year Est. Return 39.5%
This Fund
S&P 500
This Quarter Est. Return
+9.15%
1 Year Est. Return
+39.5%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$25.3M
AUM Growth
-$3.03M
Cap. Flow
-$4.59M
Cap. Flow %
-18.16%
Top 10 Hldgs %
77.23%
Holding
137
New
23
Increased
71
Reduced
13
Closed
24

Top Buys

Rank Stock Value
1
MMYT icon
MakeMyTrip
MMYT
+$1.68M
2
TK icon
Teekay
TK
+$493K
3
IBN icon
ICICI Bank
IBN
+$492K
4
NCLH icon
Norwegian Cruise Line
NCLH
+$107K
5
PRIM icon
Primoris Services
PRIM
+$86.8K

Top Sells

Rank Stock Value
1
RDY icon
Dr. Reddy's Laboratories
RDY
+$1.7M
2
HCC icon
Warrior Met Coal
HCC
+$1.55M
3
AAPL icon
Apple
AAPL
+$1.25M
4
MSFT icon
Microsoft
MSFT
+$1.07M
5
CMPR icon
Cimpress
CMPR
+$524K

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 18.16%
2 Energy 18.01%
3 Financials 13.56%
4 Healthcare 5.85%
5 Materials 5.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
HWC icon
101
Hancock Whitney
HWC
$6.23B
$25K 0.1%
523
+23
+5% +$1.05K
KNSA icon
102
Kiniksa Pharmaceuticals
KNSA
$6.24B
$24.1K 0.1%
1,292
+56
+5% +$1.05K
SUPN icon
103
Supernus Pharmaceuticals
SUPN
$2.71B
$23.5K 0.09%
878
+164
+23% +$4.75K
BLKB icon
104
Blackbaud
BLKB
$2B
$22.6K 0.09%
297
+51
+21% +$3.93K
CYH icon
105
Community Health Systems
CYH
$385M
$22K 0.09%
+6,534
New +$22K
TCMD icon
106
Tactile Systems Technology
TCMD
$632M
$20.7K 0.08%
1,735
+104
+6% +$1.4K
CPRX
107
DELISTED
Catalyst Pharmaceutical
CPRX
$20K 0.08%
1,294
+266
+26% +$4.14K
VYGR icon
108
Voyager Therapeutics
VYGR
$190M
$19.3K 0.08%
2,439
+79
+3% +$662
ATRC icon
109
AtriCure
ATRC
$2.08B
$18.4K 0.07%
810
+58
+8% +$1.34K
KRO icon
110
KRONOS Worldwide
KRO
$714M
$17.8K 0.07%
+1,420
New +$17.9K
BPMC
111
DELISTED
Blueprint Medicines
BPMC
$15.8K 0.06%
147
-16
-10% -$1.6K
XRX icon
112
Xerox
XRX
$362M
$15.2K 0.06%
1,312
+42
+3% +$610
SD icon
113
SandRidge Energy
SD
$503M
$2.06K 0.01%
159
AAL icon
114
American Airlines Group
AAL
$10B
-6,343
Closed -$97.4K
AAPL icon
115
Apple
AAPL
$5.05T
-7,265
Closed -$1.25M
AIT icon
116
Applied Industrial Technologies
AIT
$12.5B
-377
Closed -$74.5K
ATKR icon
117
Atkore
ATKR
$2.48B
-728
Closed -$139K
BYD icon
118
Boyd Gaming
BYD
$6.74B
-535
Closed -$36K
CHGG icon
119
Chegg
CHGG
$118M
-2,583
Closed -$19.6K
CMPR icon
120
Cimpress
CMPR
$2.4B
-5,919
Closed -$524K
COKE icon
121
Coca-Cola Consolidated
COKE
$12.8B
-830
Closed -$70.3K
EGHT icon
122
8x8 Inc
EGHT
$281M
-9,400
Closed -$25.4K
GLP icon
123
Global Partners
GLP
$1.67B
-616
Closed -$27.3K
HCAT icon
124
Health Catalyst
HCAT
$165M
-2,786
Closed -$21K
MSFT icon
125
Microsoft
MSFT
$2.97T
-2,552
Closed -$1.07M

Similar funds

Virtus Fund Advisers's Q2 2024 Portfolio in Review

As of Q2 2024, Virtus Fund Advisers held 137 positions worth $25.3M, down 11% from $28.3M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Virtus Fund Advisers withdrew a net $4.59M in Q2 2024, closing 24 positions and reducing 13 holdings. Its most notable exit was Dr. Reddy's Laboratories, an estimated $1.7M position sold in full.

By sector, the portfolio is most concentrated in Consumer Discretionary at 18% of assets, up from 12% a quarter earlier, followed by Energy and Financials.

Against the trend, Virtus Fund Advisers opened a new position in Norwegian Cruise Line worth $115K.

  • Virtus Fund Advisers's largest Q2 2024 buy was Norwegian Cruise Line: 6,114 shares worth $115K.
  • Virtus Fund Advisers added most to MakeMyTrip in Q2 2024, an estimated $1.68M increase.
  • Virtus Fund Advisers's biggest Q2 2024 reduction was Warrior Met Coal, cutting an estimated $1.55M.
  • Virtus Fund Advisers fully exited Dr. Reddy's Laboratories in Q2 2024, selling an estimated $1.7M.
  • Virtus Fund Advisers's ten largest holdings make up 77% of its $25.3M portfolio in Q2 2024.
  • Virtus Fund Advisers opened 23 new positions and closed 24 in Q2 2024.
  • Virtus Fund Advisers's portfolio value fell 11% quarter-over-quarter to $25.3M.

Based on Virtus Fund Advisers's 13F filing for Q2 2024, filed 14 Aug 2024.